Exos Asset Management’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

Exos Asset Management's CLDI.WS Position: Q1 2025 in Review

Exos Asset Management sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q1 2025, closing a stake of 105,000 shares — an estimated $1.01K sold.

Exos Asset Management first reported a position in CLDI.WS in Q1 2024 and held it in 4 quarters. The position peaked at $5.46K in Q1 2024. 0 funds tracked by Wall St. Rank hold CLDI.WS as of Q1 2025.

• Exos Asset Management reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q1 2025 after selling out during the quarter.
• Exos Asset Management sold 105,000 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q1 2025, an estimated $1.01K.
• Exos Asset Management first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q1 2024 and held it in 4 quarters.
• Exos Asset Management's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $5.46K in Q1 2024.
• 0 funds tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q1 2025.

Based on Exos Asset Management's 13F filing for Q1 2025, filed 15 May 2025.